Ionis Pharmaceuticals stock is trading -22.5% below its average target price of $46.94 after dropping -3.7% during today's evening session. Analysts are giving the mid-cap Pharmaceutical company an average rating of hold and target prices ranging from $24.0 to $92.0 per share.
Ionis Pharmaceuticals has an average level of shares sold short, at 6.1% of its total share float. The stock's short ratio (also called days to cover) is 7.91. Only 0.59% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders.
Institutional investors own 93.5% of Ionis Pharmaceuticals's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Ionis Pharmaceuticals
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2022-12-31 | FMR, LLC | 15% | 21,307,519 | $775,167,563 |
| 2022-12-31 | Vanguard Group, Inc. (The) | 9% | 13,546,694 | $492,828,742 |
| 2022-12-31 | T. Rowe Price Investment Management, Inc. | 8% | 11,678,259 | $424,855,074 |
| 2022-12-31 | Bellevue Group AG | 7% | 9,743,900 | $354,483,092 |
| 2022-12-31 | Blackrock Inc. | 6% | 9,079,557 | $330,314,293 |
| 2022-12-31 | ClearBridge Investments, LLC | 4% | 5,425,642 | $197,384,861 |
| 2022-12-31 | Price (T.Rowe) Associates Inc | 3% | 4,292,431 | $156,158,644 |
| 2022-12-31 | State Street Corporation | 3% | 4,218,729 | $153,477,365 |
| 2022-12-31 | Tweedy Browne Company, L.L.C. | 2% | 3,541,136 | $128,826,531 |
| 2022-12-31 | ARK Investment Management, LLC | 2% | 2,673,538 | $97,263,315 |
